COMPLERA Drug Patent Profile

When do Complera patents expire, and what generic alternatives are available?

Complera is a drug marketed by Gilead Sciences Inc and is included in one NDA. There is one patent protecting this drug and one Paragraph IV challenge.

This drug has fifty-five patent family members in thirty-seven countries.

The generic ingredient in COMPLERA is emtricitabine; rilpivirine hydrochloride; tenofovir disoproxil fumarate. There are eighteen drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the emtricitabine; rilpivirine hydrochloride; tenofovir disoproxil fumarate profile page.

DrugPatentWatch^® Generic Entry Outlook for Complera

Complera was eligible for patent challenges on May 20, 2015.

There have been sixteen patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

Summary for COMPLERA

International Patents:	55
US Patents:	1
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	2
Clinical Trials:	6
Patent Applications:	406
Drug Prices:	Drug price information for COMPLERA
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for COMPLERA
What excipients (inactive ingredients) are in COMPLERA?	COMPLERA excipients list
DailyMed Link:	COMPLERA at DailyMed

See drug prices for COMPLERA

Recent Clinical Trials for COMPLERA

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Ottawa Hospital Research Institute	Phase 3
Gilead Sciences	Phase 3
CIHR Canadian HIV Trials Network	Phase 3

See all COMPLERA clinical trials

Pharmacology for COMPLERA

Drug Class	Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor
Mechanism of Action	Non-Nucleoside Reverse Transcriptase Inhibitors Nucleoside Reverse Transcriptase Inhibitors

Paragraph IV (Patent) Challenges for COMPLERA

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
COMPLERA	Tablets	emtricitabine; rilpivirine hydrochloride; tenofovir disoproxil fumarate	200 mg/25 mg/ 300 mg	202123	1	2015-05-20

US Patents and Regulatory Information for COMPLERA

COMPLERA is protected by one US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Gilead Sciences Inc	COMPLERA	emtricitabine; rilpivirine hydrochloride; tenofovir disoproxil fumarate	TABLET;ORAL	202123-001	Aug 10, 2011	AB	RX	Yes	Yes	10,857,102		Y

Expired US Patents for COMPLERA

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Gilead Sciences Inc	COMPLERA	emtricitabine; rilpivirine hydrochloride; tenofovir disoproxil fumarate	TABLET;ORAL	202123-001	Aug 10, 2011	8,101,629
Gilead Sciences Inc	COMPLERA	emtricitabine; rilpivirine hydrochloride; tenofovir disoproxil fumarate	TABLET;ORAL	202123-001	Aug 10, 2011	8,592,397
Gilead Sciences Inc	COMPLERA	emtricitabine; rilpivirine hydrochloride; tenofovir disoproxil fumarate	TABLET;ORAL	202123-001	Aug 10, 2011	6,838,464
Gilead Sciences Inc	COMPLERA	emtricitabine; rilpivirine hydrochloride; tenofovir disoproxil fumarate	TABLET;ORAL	202123-001	Aug 10, 2011	8,716,264
Gilead Sciences Inc	COMPLERA	emtricitabine; rilpivirine hydrochloride; tenofovir disoproxil fumarate	TABLET;ORAL	202123-001	Aug 10, 2011	7,125,879
Gilead Sciences Inc	COMPLERA	emtricitabine; rilpivirine hydrochloride; tenofovir disoproxil fumarate	TABLET;ORAL	202123-001	Aug 10, 2011	8,080,551

International Patents for COMPLERA

When does loss-of-exclusivity occur for COMPLERA?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

African Regional IP Organization (ARIPO)

Argentina

Australia

Brazil

Canada

Chile

China

Colombia

Costa Rica

Croatia

Cyprus

Denmark

Ecuador

Eurasian Patent Organization

European Patent Office

Hong Kong

Israel

Japan

Malaysia

Mexico

Montenegro

Morocco

New Zealand

Peru

Philippines

Poland

Portugal

San Marino

Serbia

Singapore

Slovenia

South Africa

South Korea

Spain

Taiwan

Ukraine

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering COMPLERA around the world.

Country	Patent Number	Title	Estimated Expiration
African Regional IP Organization (ARIPO)	3816
Argentina	084500
Argentina	123409
Australia	2011329642
Australia	2016208417
Australia	2018202635

Supplementary Protection Certificates for COMPLERA

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1419152	C300529	Netherlands		PRODUCT NAME: RILPIVIRINE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ADDITIEZOUT, IN HET BIJZONDER HET HYDROCHLORIDEZOUT; REGISTRATION NO/DATE: EU/1/11/736/001 20111128
1419152	C300532	Netherlands		PRODUCT NAME: EEN COMBINATIE VAN RILPIVIRINE EN ELKE DOOR HET BASISOCTROOI BESCHERMDE THERAPEUTISCH EQUIVALENTE VORM DAARVAN,; REGISTRATION NO/DATE: EU/1/11/737/001-002 20111128
1419152	PA2012008	Lithuania		PRODUCT NAME: RILPIVIRINUM; REGISTRATION NO/DATE: EU/1/11/736/001 20111128
1419152	PA2012009	Lithuania		PRODUCT NAME: EMTRICITABINUM + RILPIVIRINUM + TENOFOVIRUM DISOPROXILUM; REGISTRATION NO/DATE: EU/1/11/737/001, 2011 11 28 EU/1/11/737/002 20111128
1419152	CA 2012 00021	Denmark
1419152	CA 2012 00019	Denmark

COMPLERA (emtricitabine/rilpivirine/tenofovir disoproxil fumarate) market dynamics and financial trajectory

Last updated: June 14, 2026

COMPLERA (emtricitabine/rilpivirine/tenofovir disoproxil fumarate, “FTC/RPV/TDF”) is a first-line HIV combination anchored on rilpivirine (RPV) plus FTC and TDF. The brand’s financial trajectory has been driven by (1) lifecycle displacement by newer HIV regimens, particularly long-acting injectables and integrase inhibitor-based fixed-dose combinations, (2) shifting payer and guideline preference toward regimens with fewer food and resistance constraints, and (3) geographic and channel effects from generic erosion. RPV/TDF-based fixed-dose triple therapy lost share as integrase inhibitor (INSTI) regimens with higher barriers to viral rebound and simplified administration became first-line norms.

How has COMPLERA’s revenue trended since launch?

Answer: COMPLERA’s sales have trended down over time as generic versions of FTC/RPV/TDF entered and as prescribers shifted to INSTI-based and long-acting regimens. Price pressure followed generic entry, while market share erosion accelerated as treatment guidelines moved away from older NRTI backbones and boosted uptake of higher-gen regimens.

What drove COMPLERA’s market share loss?

Key demand headwinds have been consistent with the HIV market’s shift toward INSTI-centered therapy:

• Guideline migration to INSTI-based regimens: INSTI combinations became preferred due to efficacy, durability, and tolerability profiles that improved real-world prescribing behavior.
• Food and dosing constraints tied to rilpivirine: RPV requires administration with food to achieve adequate exposure. That reduces convenience versus some competing regimens and creates dosing friction that can lower switch rates.
• Resistance and baseline susceptibility considerations: RPV-based therapy requires attention to viral load and resistance markers; when clinicians perceive higher risk of virologic failure, they tend to favor alternative classes.
• Generic availability of components and the fixed-dose combination: As FTC/RPV/TDF secured generic competition, brand pricing power eroded and payer formulary positioning likely shifted to lower-cost alternatives.

Which competitors pressured COMPLERA?

COMPLERA has faced competitive pressure primarily from:

• Single-tablet INSTI-based regimens (high uptake due to guideline preference)
• Long-acting injectable therapies that reduce daily adherence burden
• Generic fixed-dose ART options at materially lower price points that captured high-volume segments where clinical differentiation is limited

What patents or exclusivity affected COMPLERA’s commercial lifecycle?

Answer: The commercial lifecycle of COMPLERA has been shaped by expiration of composition and formulation IP covering FTC/RPV/TDF fixed-dose combinations, plus any regulatory exclusivity that delayed generic competition for specific filings or strengths. After those barriers cleared, generic entry drove down net prices and volumes for the brand.

How do patent and exclusivity timelines translate into revenue impact?

When fixed-dose combination IP expires, generic fixed equivalents typically enter quickly, compressing:

• Net revenue per prescription (discounting and payer steering)
• Share-of-voice on formularies
• Channel economics for wholesalers and pharmacy benefit managers

Where do patent estates usually concentrate in HIV fixed-dose combinations?

Typical IP clusters for HIV fixed-dose products include:

• Composition of matter for the combination or specific salts/polymorphs
• Formulation patents tied to fixed-dose stability, dissolution, and bioavailability
• Method-of-use patents linked to dosing, patient selection, or treatment sequences

When did COMPLERA face generic erosion, and how did it affect pricing?

Answer: Generic erosion is the dominant factor behind COMPLERA’s long-run revenue compression. Once generic FTC/RPV/TDF entered, the brand’s gross-to-net dynamics deteriorated as payers moved to cost-minimizing coverage policies.

What does generic entry usually do to net price and margins?

In branded HIV fixed-dose products:

• Wholesale acquisition cost typically declines or is discounted more aggressively to protect coverage.
• PBM rebate pressure increases, raising the share of revenue consumed by contracting.
• Non-Medicaid commercial and Medicare segments shift first, then Medicaid follows as state formularies update.

What demand segments are most resilient during generic transitions?

• Patients stable on the brand can remain on therapy temporarily due to switch cost or clinician preference.
• Coverage gaps and utilization controls can delay forced switching, but these typically resolve as payers refresh formularies.

How does COMPLERA compare with newer HIV regimens in efficacy, dosing convenience, and switching behavior?

Answer: Compared with newer INSTI-based combinations and long-acting regimens, COMPLERA generally faces disadvantage on convenience and prescribing momentum. Those attributes influence patient retention and clinician switching patterns, accelerating share loss even when virologic outcomes remain strong in appropriate candidates.

Why do dosing and food requirements matter commercially?

For rilpivirine-containing regimens:

• Food requirements create daily adherence friction.
• Payers and clinicians often prefer regimens with fewer behavioral constraints, especially in populations with variable food access.

How do resistance-risk perceptions affect uptake?

Even with strong clinical performance in indicated populations, perceived virologic risk and baseline requirements can push clinicians toward INSTI regimens.

What is the Orange Book status of COMPLERA, and what generic entry risks exist?

Answer: COMPLERA’s fixed-dose IP has largely permitted generic entry in the market, creating ongoing generic competition risk for any remaining brand exclusivity. The relevant risk is not “future” entry so much as:

• share capture by multiple generic manufacturers
• continued price compression through parallel competition

How to interpret Orange Book signals for a displaced brand

For legacy HIV combinations, Orange Book listings often show:

• Remaining patents that are formulation- or method-of-use focused
• Industry behavior shifts to “design-around” strategies that avoid protected parameters, then compete on price

What formulations or patient-selection patents could still matter for COMPLERA?

Answer: For an established HIV fixed-dose product, the remaining meaningful IP typically sits in:

• Formulation improvements (bioavailability, stability, particle size)
• Patient selection or dosing regimens (conditions on baseline parameters and dosing conditions)
• Manufacturing and scale-up methods

Why formulation IP can still affect commercial outcomes

Even if a composition-of-matter patent expires, formulation or method-of-use barriers can:

• Delay certain generics
• Limit automatic interchangeability in practice
• Create product line complexity that slows pure price erosion

How do payer formularies and Medicare Part D policies affect COMPLERA sales?

Answer: Payer controls usually accelerate decline for older, higher-cost HIV products once generics become preferred. Medicare Part D and commercial formularies commonly steer usage to lower-cost equivalents unless clinical exceptions are established.

What formulary levers matter most?

• Preferred product tiers and step therapy
• Prior authorization criteria tied to clinical justification
• Quantity limits aligned to low-cost alternatives

What does the COMPLERA financial trajectory imply for investment and licensing decisions?

Answer: For investors and licensors, COMPLERA functions as a case study in long-tail decline driven by generic competition and class switching in HIV care. Any valuation or licensing of COMPLERA-adjacent IP is typically more sensitive to:

• whether remaining patents can sustain exclusivity in specific formulations or method-of-use claims
• whether a differentiated next-generation regimen can capture protected segments

Where licensing tends to concentrate in legacy HIV products

Licensing activity often shifts from brand economics to:

• new formulations and combinations
• improved delivery (stability, tolerability, food effects mitigation)
• lifecycle management assets with clear regulatory and IP pathways

What litigation or settlements have influenced COMPLERA’s competitive position?

Answer: In mature HIV fixed-dose categories, Paragraph IV challenges and related settlements often determine timing of generic entry and can create delayed launches. For COMPLERA, the broad market pattern is that generic competition proceeded as IP barriers cleared, reducing brand economics.

What litigation outcomes typically drive revenue outcomes

• Automatic stay periods delaying generic launch
• Settlement-based launch dates that define when price erosion begins
• Court outcomes that either confirm generic infringement or allow entry sooner than expected

How does COMPLERA’s competitive landscape vary by geography?

Answer: Revenue effects depend on local regulatory approval statuses, reimbursement rules, and patent enforceability. In high-income markets with rapid generic uptake, the brand faces faster erosion. In systems with slower formulary updates or longer regulatory review, erosion can be delayed but still trends downward.

What geography patterns usually emerge for fixed-dose HIV brands

• Faster decline in markets with high generic penetration and tender-driven procurement
• More persistent share where clinician inertia and patient stability reduce switching velocity

Key Takeaways

• COMPLERA’s long-run financial trajectory has been shaped by generic erosion and HIV treatment class migration toward INSTI-based and long-acting regimens.
• The brand’s decline typically accelerates when payers steer usage away from costlier fixed-dose options and when prescribing behavior shifts due to dosing convenience and resistance-risk considerations tied to rilpivirine.
• Remaining commercial value is usually constrained to patient retention and any residual formulation or method-of-use IP, while broader market dynamics increasingly favor lower-cost, guideline-aligned therapy.

FAQs

1) What drove COMPLERA volume decline more: guideline changes or generic competition?

Answer: Generic competition drives sustained pricing pressure, while guideline migration drives persistent share loss by changing prescriber preference and switching behavior.

2) How does COMPLERA’s rilpivirine component affect real-world adherence versus INSTI regimens?

Answer: Food requirements and baseline susceptibility considerations create day-to-day friction and increase clinician caution compared with many INSTI options.

3) Do long-acting HIV injectables reduce COMPLERA’s target population?

Answer: Yes. Patients eligible for long-acting therapy often shift away from daily oral regimens, reducing the addressable market for older triple fixed-dose products.

4) What is the main commercial consequence of Paragraph IV-driven generic launches in legacy HIV fixed-dose drugs?

Answer: Lower net pricing from payer steering to generics plus faster formulary tier movement that compresses brand volumes.

5) Where can a legacy HIV fixed-dose brand still retain value after generic entry?

Answer: Through patient stability, clinician preference in specific subpopulations, and any remaining differentiating IP that limits direct interchangeability in certain formulations or indications.

References

1. U.S. Food and Drug Administration. (n.d.). Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. https://www.accessdata.fda.gov/scripts/cder/daf/
2. FDA. (n.d.). Drug Approval Reports and Labeling (COMPLERA). https://www.accessdata.fda.gov/

DrugChatter Q&A for COMPLERA

Is there a generic for Complera?